将最新的 CIRM 新闻、即将召开的会议的信息以及资金机会发送到您的收件箱。

Objetivo de la investigación Células CAR-iNKT (AlloMCAR-iNKT) dirigidas a mesotelina alogénica diseñada por HSC Impacto en el tratamiento del cáncer de ovario Principales actividades propuestas Hito 1 ...

CIRM funds stem cell research to institutions throughout California. On the map below, click on any marker to learn more about our funding to that institution. You can explore the awards they’ve ...

The mission of the California Institute for Regenerative Medicine (CIRM) is to accelerate world class science to deliver transformative regenerative medicine treatments in an equitable manner to a ...

Jonathan Thomas, PhD, JD, is President and CEO of the California Institute for Regenerative Medicine (CIRM). Thomas was previously the Chair of the CIRM governing Board from June 2011 to March 2023.

Welcome to the frequently asked questions (FAQs) page of the California Institute for Regenerative Medicine (CIRM). Here, you’ll find answers to the most common questions you may have on CIRM. CIRM, ...

The mission of the California Institute for Regenerative Medicine (CIRM) is to accelerate world class science to deliver transformative regenerative medicine treatments in an equitable manner to a ...

Foundation – Discovery Stage Research Projects Qiong Annabel Wang Utilizing Age-Specific Adipocyte Progenitor Cells for Cell Therapy in Older Patients $1,508,997 Research Training Grant Dr. Michael E.

Through its strategic funding of clinical trials, CIRM helps advance innovative stem cell and gene therapy discoveries toward future treatments for patients. CIRM funds clinical trials across a broad ...

The mission of California Institute for Regenerative Medicine (CIRM) is to accelerate world class science to deliver transformative regenerative medicine treatments in an equitable manner to a diverse ...

At the California Institute for Regenerative Medicine (CIRM), we are committed to the continued funding of groundbreaking research in regenerative medicine. To reflect this commitment, we are ...

Autologous iPSC-derived dopaminergic progenitor cells represent a promising strategy to replace the nigrostriatal cells which are lost in Parkinson's Disease (PD). While approaches using fetal tissue ...